Antitumor activity and pharmacokinetics following oral administration of natural product DNA topoisomerase I inhibitors 10-hydroxycamptothecin and camptothecin in SCID mice bearing human breast cancer xenografts

International Journal of Oncology

Volumn 10, Issue 6, 1997, Pages 1147-1156

  Zhang, Ruiwen ^a,b   Cai, Qiuyin ^a,b   Russell Lindsey, J ^a   Li, Yufeng ^a,b   Chambless, Brandon ^a,b   Naguib, Fardos N M ^a,b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b Box 600 ^*  (United States)

Author keywords

Breast cancer; Camptothecins; Chemotherapy; Oral drug delivery; Pharmacokinetics

Indexed keywords

10 HYDROXYCAMPTOTHECIN; CAMPTOTHECIN; DNA TOPOISOMERASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG TISSUE LEVEL; FEMALE; HISTOLOGY; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SCID MOUSE; TUMOR XENOGRAFT;

EID: 0030992128     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.10.6.1147     Document Type: Article

References (23)

1. Wall ME, Wani MC, Cook CE, Palmer KH, Mcphail AT and Sim GA: Plant antitumor agents: I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata. J Am Chem Soc 88: 3888-3890, 1966.
2. Gottlich JA, Guarino AM, Call JB and Block JB: Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC-100880). Cancer Chemother Rep 54: 461-470, 1970.
3. Creven PR, Allen LM and Muggia FM: Plasma camptothecin (NSC-100880) levels during a 5-day course of treatment: relation to dose and toxicity. Cancer Chemother Rep 56: 573-578, 1972.
4. Creaven PR and Allen LM: Renal clearance of camptothecin (NSC-100880): effect of urine volume. Cancer Chemother Rep 57: 175-184, 1973.
5. Muggia FM, Creaven PJ, Hansen HH, Cohen MH and Selawry OS: Phase I clinical trial weekly and daily treatment of camptothecin (NSC-100880): correlation with preclinical studies. Cancer Chemother Rep 56: 515-521, 1972.
6. Moertel CG, Schutt AJ, Reitemeier RJ and Hahn RG: Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer. Cancer Chemother Rep 56: 95-101, 1972.
7. Gottlieb JA and Luce JK: Treatment of malignant of melanoma with camptothecin (NSC-100880). Cancer Chemother Rep 56: 103-105, 1972.
8. Hsiang YH, Hertzberg R, Hecht S and Liu LF: Camptothecin induced protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 260: 14873-14878, 1985.
9. Chabner B A: Camptothecin. J Clin Oncol 10: 3-4, 1992.
10. Slichnmyer WR, Rowinsky EK, Donehower RC and Kaufmann SH: The current status of camptothecin analogues as antitumor agents. J Natl Cancer Inst 85: 271-291, 1993.
11. Creemers GJ, Lund B and Verweij J: Topoisomerase I inhibitors: topotecan and irinotecan. Cancer Treatment Rev 20: 73-96, 1994.
12. Potmesil M: Camptothecin from bench research to hospital wards. Cancer Res 54: 1431-1439, 1994.
13. Han R: Highlight on the studies of anticancer drugs derived from plants in China. Stem Cells 12: 53-63, 1994.
14. Wani MC, Nicholas AW, Manikumar G and Wall ME: Plant antitumor agents: 25. Total synthesis and antileukemic activity of ring A substituted camptothecin analogues. Structure-activity correlations. J Med Chem 30: 1774-1779, 1987.
15. Jaxel C, Kuhn KW, Wani MC, Wall ME and Pommier Y: Structure-activity study of the actions of camptothecin derivatives of mammalian topoisomerase I: evidence for specific receptor site and a relation to antitumor activity. Cancer Res 49: 1465-1469, 1989.
16. Hertzberg RP, Caranfa MJ, Holden KG, Jakas DR, Gallagher G, Mattern MR, Mong SM, Bartus JO, Johnson RK and Kingsbury WD: Modification of the hydroxy lactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity. J Med Chem 32: 715-720, 1989.
17. Hertzberg RP, Caranfa MJ and Hecht SM: On the mechanism of topoisomerase I inhibition by camptothecin: evidence for binding to an enzyme-DNA complex. Biochemistry 28: 4629-4638, 1989.
18. Pantazis P: Preclinical studies of water-insoluble camptothecin congeners: cytotoxicity, development of resistance, and combination treatment. Clin Cancer Res 1: 1235-1244, 1995.
19. Potmesil M and Glovanella BC: Preclinical development of 20(S)-camplothecin, 9-aminocamptothecin, and other analogues. In: Camptothecins: New Anticancer Agents. Potmesil M and Pinedo H (eds). CRC Press, Boca Raton, FL, pp41-57, 1995.
20. Giovanella BC, Hinz HR, Kozielski AJ, Stehlin JS, Slilber R and Potmesil M: Complete growth inhibition of human cancer xenografts in nude mice by treatment with 20(S)-camptothecin. Cancer Res 51: 3052-3055, 1991.
21. Potmesil M, Vardeman D, Kozielski AJ, Mendoza J, Stehlin JS and Giovanella BC: Growth inhibition of human cancer metastases by camptothecins in newly developed xenograft models. Cancer Res 55: 5637-5641, 1995.
22. Stehlin JS, Natelson EA, Hinz HR, Giovanella CG, De Ipolyi PD, Fehir KM, Trezona TP, Vardeman DM, Harris NJ, Marcee AK, Kozielski AJ and Ruiz-Razura A: Phase I clinical trial and pharmacokinetics results with oral administration of 20(S)camptothecin. In: Camptothecins: New Anticancer Agents. Potmesil M and Pinedo H (eds). CRC Press, Boca Raton, FL, pp59-65, 1995.
23. Wall ME and Wani MC: Camptothecin and analogs: from discovery to clinic. In: Camptothecins: New Anticancer Agents. Potmesil M and Pinedo H (eds). CRC Press, Boca Raton, FL, pp21-41, 1995.